Seqirus Netherlands B.V.
7 products tracked · names used in filings: Seqirus Netherlands B.V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Thu 20 Aug 2026🇪🇺 EU approval (EC decision)
Aujemflu (Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture)) approved in the EU
Marketing authorisation to Seqirus Netherlands B.V. · source
Thu 25 Jun 2026🇪🇺 CHMP positive opinion
Aujemflu (Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture)): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Aujemflu Influenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture) | Authorised | 2026-08-20 |
| 🇪🇺 | Fluad influenza vaccine (surface antigen, inactivated, adjuvanted) | Authorised | 2024-11-15 |
| 🇪🇺 | Flucelvax influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Authorised | 2024-11-15 |
| 🇪🇺 | Celldemic zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) | Authorised | 2024-04-19 |
| 🇪🇺 | Incellipan pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) | Authorised | 2024-04-19 |
| 🇪🇺 | Fluad Tetra influenza vaccine (surface antigen, inactivated, adjuvanted) | Withdrawn | 2020-05-20 |
| 🇪🇺 | Flucelvax Tetra influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Withdrawn | 2018-12-12 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.